MyFinsight
Home
About
Contact
anab: the income statement
Download
Download image
Preclinical And Other
Unallocated Costs
$3,813K
ANB101
$1,784K
ANB033
$7,519K
Rosnilimab
$7,070K
Internal Expenses
$7,962K
External Expenses
$2,247K
Internal Expenses
$12,787K
External Expenses
$18,620K
Imsidolimab
-$1,204K
ANB032
-$362K
General and
administrative
$10,209K
Research and development
$31,407K
Income (loss) from
operations
$34,704K
Total operating
expenses
$41,616K
Collaboration revenue
$76,320K
(154.26%↑ Y/Y)
Income (loss) from
operations
$34,704K
(252.50%↑ Y/Y)
Total operating
expenses
$41,616K
(-21.14%↓ Y/Y)
Income (loss) before
income taxes
$15,113K
(146.00%↑ Y/Y)
Total other expense,
net
-$19,591K
(-94.09%↓ Y/Y)
Interest income
$2,924K
(-45.08%↓ Y/Y)
General and
administrative
$10,209K
(-3.34%↓ Y/Y)
Research and development
$31,407K
(-25.60%↓ Y/Y)
Unrealized gain (loss) on
available for sale...
$53K
(-95.49%↓ Y/Y)
Net income (loss)
$15,113K
(146.00%↑ Y/Y)
Non-cash interest
expense for the sale of...
$22,515K
(46.08%↑ Y/Y)
Comprehensive income (loss)
$15,166K
(147.88%↑ Y/Y)
Back
Back
Income Statement
source: myfinsight.com
ANAPTYSBIO, INC (ANAB)
ANAPTYSBIO, INC (ANAB)